Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW)
Shots:
- Beigene to get exclusive development and commercialization rights to ZW’s ZW25 and ZW49 candidates in Asia- New Zealand and Australia (ex. Japan). ZW to receive $40M upfront- $390M milestones and tiered royalties on sales
- Also- Beigene to get WW rights of ZW’s Azymetric & EFECT platforms- to develop up to three bispecific Abs and ZW to receive $20M upfront- $702M milestone plus royalties on global sales
- ZW49 is a bispecific pre-clinical candidate targeting two non-overlapping epitopes of HER2. ZW25 is a P-I candidate developed using Azymetric platform- used for binding two non-overlapping epitopes of HER2
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
